{"id":134275,"date":"2021-08-03T14:15:21","date_gmt":"2021-08-03T14:15:21","guid":{"rendered":"https:\/\/precoinnews.com\/?p=134275"},"modified":"2021-08-03T14:15:21","modified_gmt":"2021-08-03T14:15:21","slug":"cathie-woods-ark-invest-buys-over-850000-shares-of-pacific-bio","status":"publish","type":"post","link":"https:\/\/precoinnews.com\/markets\/cathie-woods-ark-invest-buys-over-850000-shares-of-pacific-bio\/","title":{"rendered":"Cathie Wood’s ARK Invest Buys Over 850,000 Shares of Pacific Bio"},"content":{"rendered":"
A couple of ARK Invest exchange-traded funds run by ETF star Cathie Wood bought over 850,000 shares of Pacific Biosciences of California Inc. (NASDAQ: PACB) altogether on Monday, as the prices of these ETFs were up less than 1% in Monday\u2019s session. These funds are up a fair amount in the past year.<\/p>\n
ARK Genomic Revolution ETF (NYSEARCA: ARKG) bought 96,000 shares, while ARK Innovation ETF (NYSEARCA: ARKK) bought 756,850 shares. At Monday\u2019s closing price, this would have valued these purchases at roughly $26.6 million altogether. This is only a small fraction of the total holdings. ARKG is up roughly 59% in the past year and ARKK is up 53%.<\/p>\n
Check out all of ARK Invest\u2019s buys for Monday:<\/p>\n
Fund<\/th>\n | Ticker<\/th>\n | Company<\/th>\n | Shares<\/th>\n<\/tr>\n<\/thead>\n |
---|---|---|---|
ARKF<\/td>\n | ETSY<\/td>\n | Etsy<\/td>\n | 64,213<\/td>\n<\/tr>\n |
ARKG<\/td>\n | VERV<\/td>\n | Verve Therapeutics<\/td>\n | 94,600<\/td>\n<\/tr>\n |
ARKG<\/td>\n | SURF<\/td>\n | Surface Oncology<\/td>\n | 14,000<\/td>\n<\/tr>\n |
ARKG<\/td>\n | SMFR<\/td>\n | Sema4<\/td>\n | 551,578<\/td>\n<\/tr>\n |
ARKG<\/td>\n | SGFY<\/td>\n | Signify Health<\/td>\n | 102,356<\/td>\n<\/tr>\n |
ARKG<\/td>\n | RPTX<\/td>\n | Repare Therapeutics<\/td>\n | 5,897<\/td>\n<\/tr>\n |
ARKG<\/td>\n | QSI<\/td>\n | Quantum-Si<\/td>\n | 70,000<\/td>\n<\/tr>\n |
ARKG<\/td>\n | PACB<\/td>\n | Pacific Biosciences of California<\/td>\n | 96,000<\/td>\n<\/tr>\n |
ARKG<\/td>\n | FATE<\/td>\n | Fate Therapeutics<\/td>\n | 27,556<\/td>\n<\/tr>\n |
ARKG<\/td>\n | CMIIU<\/td>\n | CM Life Sciences II<\/td>\n | 5,000<\/td>\n<\/tr>\n |
ARKG<\/td>\n | EDIT<\/td>\n | Editas Medicine<\/td>\n | 30,356<\/td>\n<\/tr>\n |
ARKG<\/td>\n | MASS<\/td>\n | 908 Devices<\/td>\n | 10,671<\/td>\n<\/tr>\n |
ARKK<\/td>\n | VCYT<\/td>\n | Veracyte<\/td>\n | 11,405<\/td>\n<\/tr>\n |
ARKK<\/td>\n | PD<\/td>\n | PagerDuty<\/td>\n | 167,000<\/td>\n<\/tr>\n |
ARKK<\/td>\n | PACB<\/td>\n | Pacific Biosciences of California<\/td>\n | 756,850<\/td>\n<\/tr>\n |
ARKK<\/td>\n | CRSP<\/td>\n | CRISPR Therapeutics<\/td>\n | 55,000<\/td>\n<\/tr>\n |
ARKK<\/td>\n | BEAM<\/td>\n | Beam Therapeutics<\/td>\n | 81,497<\/td>\n<\/tr>\n |
ARKQ<\/td>\n | MKFG<\/td>\n | Markforged<\/td>\n | 18,200<\/td>\n<\/tr>\n |
ARKQ<\/td>\n | PATH<\/td>\n | UiPath<\/td>\n | 283,325<\/td>\n<\/tr>\n |
ARKQ<\/td>\n | SPFR<\/td>\n | Jaws Spitfire Acquisition<\/td>\n | 74,000<\/td>\n<\/tr>\n |
ARKQ<\/td>\n | U<\/td>\n | Unity Software<\/td>\n | 166,740<\/td>\n<\/tr>\n |
ARKQ<\/td>\n | LMT<\/td>\n | Lockheed Martin<\/td>\n | 57,202<\/td>\n<\/tr>\n |
ARKQ<\/td>\n | IRDM<\/td>\n | Iridium Communications<\/td>\n | 202,159<\/td>\n<\/tr>\n |
ARKQ<\/td>\n | AVAV<\/td>\n | AeroVironment<\/td>\n | 15,267<\/td>\n<\/tr>\n |
ARKW<\/td>\n | VUZI<\/td>\n | Vuzix<\/td>\n | 99,712<\/td>\n<\/tr>\n |
ARKW<\/td>\n | PD<\/td>\n | PagerDuty<\/td>\n | 43,000<\/td>\n<\/tr>\n |
ARKW<\/td>\n | KVSB<\/td>\n | Khosla Venture Acquisition II<\/td>\n | 90,000<\/td>\n<\/tr>\n |
ARKW<\/td>\n | TWLO<\/td>\n | Twilio<\/td>\n | 31,572<\/td>\n<\/tr>\n |
ARKW<\/td>\n | ETSY<\/td>\n | Etsy<\/td>\n | 61,144<\/td>\n<\/tr>\n |
ARKW<\/td>\n | CND<\/td>\n | Concord Acquisition<\/td>\n | 35,000<\/td>\n<\/tr>\n |
ARKX<\/td>\n | AMZN<\/td>\n | Amazon.com<\/td>\n | 373<\/td>\n<\/tr>\n |
ARKX<\/td>\n | LMT<\/td>\n | Lockheed Martin<\/td>\n | 5,784<\/td>\n<\/tr>\n |
ARKX<\/td>\n | SPFR<\/td>\n | Jaws Spitfire Acquisition<\/td>\n | 16,000<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n \nCatherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24\/7 Wall St.<\/em><\/p>\n \t\t\t<\/p>\n \t\t\t\tALSO READ: 5 Favorite Dividend-Paying Banks to Buy Now With Q2 Earnings Over \t\t\t\t |